| Dr Deepa Jeyakumar, MD | |
|
101 The City Dr S Bldg 23, Orange, CA 92868-3201 | |
| (714) 456-5153 | |
| Not Available |
| Full Name | Dr Deepa Jeyakumar |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 19 Years |
| Location | 101 The City Dr S Bldg 23, Orange, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356541502 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | A121651 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of California Irvine Medical Center | Orange, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Uc Regents | 7416869516 | 205 |
News Archive
Skin cancers often contain different gene mutations, but just how these mutations contribute to the cause of melanomas has been a mystery.
The call to eliminate all funding for HIV/AIDS vaccine research and prevention programs and "shifting" those funds to the expansion of HIV/AIDS treatment is a "dangerous sentiment" that is "sweeping over the AIDS establishment," Laurie Garrett, a senior fellow for global health at the Council on Foreign Relations, writes in an International Herald Tribune opinion piece.
YEDA Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist - PAS-YNSα8 - which has been jointly developed by scientists at the Weizmann Institute and XL-protein.
Researchers from RUDN University and Institute of Biomedical Chemistry of the Russian Academy of Sciences have identified an alternative mechanism for the effective antitumor drug - an enzyme called L-asparaginase.
› Verified 2 days ago
| Entity Name | Uc Regents |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760430847 PECOS PAC ID: 7416869516 Enrollment ID: O20031118000906 |
News Archive
Skin cancers often contain different gene mutations, but just how these mutations contribute to the cause of melanomas has been a mystery.
The call to eliminate all funding for HIV/AIDS vaccine research and prevention programs and "shifting" those funds to the expansion of HIV/AIDS treatment is a "dangerous sentiment" that is "sweeping over the AIDS establishment," Laurie Garrett, a senior fellow for global health at the Council on Foreign Relations, writes in an International Herald Tribune opinion piece.
YEDA Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist - PAS-YNSα8 - which has been jointly developed by scientists at the Weizmann Institute and XL-protein.
Researchers from RUDN University and Institute of Biomedical Chemistry of the Russian Academy of Sciences have identified an alternative mechanism for the effective antitumor drug - an enzyme called L-asparaginase.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Deepa Jeyakumar, MD 200 S Manchester Ave Ste 300, Orange, CA 92868-3219 Ph: (714) 456-2986 | Dr Deepa Jeyakumar, MD 101 The City Dr S Bldg 23, Orange, CA 92868-3201 Ph: (714) 456-5153 |
News Archive
Skin cancers often contain different gene mutations, but just how these mutations contribute to the cause of melanomas has been a mystery.
The call to eliminate all funding for HIV/AIDS vaccine research and prevention programs and "shifting" those funds to the expansion of HIV/AIDS treatment is a "dangerous sentiment" that is "sweeping over the AIDS establishment," Laurie Garrett, a senior fellow for global health at the Council on Foreign Relations, writes in an International Herald Tribune opinion piece.
YEDA Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist - PAS-YNSα8 - which has been jointly developed by scientists at the Weizmann Institute and XL-protein.
Researchers from RUDN University and Institute of Biomedical Chemistry of the Russian Academy of Sciences have identified an alternative mechanism for the effective antitumor drug - an enzyme called L-asparaginase.
› Verified 2 days ago
Michael Cheng, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-456-7110 | |
Harry Nguyen, D.O. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-456-7002 | |
Millie Arora, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, City Tower, Suite 400, Orange, CA 92868 Phone: 714-456-5691 Fax: 714-456-8874 | |
Dr. Sarah Jeanette Ettinger, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-456-5135 | |
Dr. Antonio Halais Frangieh, MD, MPH Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-456-7890 | |
Dr. Andy Yen-tang Lee, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-456-7890 | |
Dr. Jesse John Goitia Jr., M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-880-7812 |